WuXi Biologics and Boostimmune Forge Exclusive R&D Partnership
China-based Contract Research, Development, and Manufacturing Organization (CRDMO) WuXi Biologics (HKG: 2269) has announced a...
HKG: 2269
WuXi Biologics Proposes Spin-Off and Listing of WuXi XDC on Hong Kong Stock Exchange
China-based Contract Research, Development, and Manufacturing Organization (CRDMO) WuXi Biologics (HKG: 2269) has announced the...
WuXi Biologics Partners with Pharmadule Morimatsu AB for CRDMO Expansion in Singapore
China-based WuXi Biologics (HKG: 2269) has announced a strategic partnership with Sweden-headquartered Pharmadule Morimatsu AB...
WuXi Biologics Reports 48.4% Revenue Growth in 2022 Financial Report
China-based WuXi Biologics (HKG: 2269) released its 2022 financial report for the period ending December...
CANbridge Pharmaceuticals Initiates Phase II Dosing for CAN103 in Gaucher Disease
China-based CANbridge Pharmaceuticals, Inc. (HKG: 1228) has announced the first patient dosing in the Phase...
WuXi Biologics CEO Outlines Growth Amid Global Challenges at J.P. Morgan Conference
China-based WuXi Biologics (HKG: 2269) delivered a speech at the J.P. Morgan Healthcare Conference, where...
Meheco’s Genertec Partners with AstraZeneca for COVID-19 Antibody Evusheld in China
China Meheco Group Co., Ltd (SHA: 600056) announced that its subsidiary Genertec Meheco has entered...
WuXi Biologics and GSK Ink Licensing Agreement for T-Cell Engaging Antibodies
China-based WuXi Biologics (HKG: 2269) has announced a licensing agreement with GSK plc (NYSE: GSK),...
WuXi Biologics Receives First GMP Certificate from Ireland HPRA
China-based Contract Research, Development, and Manufacturing Organization (CRDMO) WuXi Biologics (HKG: 2269) has announced receiving...
WuXi XDC Partners with GeneQuantum for ADC Development
China-based WuXi XDC, a joint venture between Wuxi Biologics (HKG: 2269) and WuXi STA, a...
WuXi Biologics’ Shanghai Subsidiary Removed from US UVL
China-based Contract Research, Development and Manufacturing Organization (CRDMO) WuXi Biologics (HKG: 2269) announced that its...
WuXi Biologics Launches Integrated Biologics CRDMO Center in Shanghai
China-based Contract Research, Development, and Manufacturing Organization (CRDMO) WuXi Biologics (HKG: 2269) has launched its...
Harbour BioMed and WuXi Biologics Announce Strategic Collaboration
Harbour BioMed (HKG: 2142), a global biotechnology company with operations in the United States, the...
WuXi Biologics Partners with Toregem BioPharma on Anti-USAG-1 Monoclonal Antibody
China-based Contract Research, Development, and Manufacturing Organization (CRDMO) WuXi Biologics (HKG: 2269) has entered into...
WuXi Biologics Removed from US Unverified List Amid Ongoing Restrictions
The US Commerce Department’s Bureau of Industry and Security (BIS) has updated its Unverified List...
WuXi Biologics Partners with neoX Biotech to Advance AI-Driven Drug Development
China-based Contract Research, Development, and Manufacturing Organization (CRDMO) WuXi Biologics (HKG: 2269) has entered into...
WuXi Biologics Partners with Elpiscience for Macromolecule Development
China-based Contract Research, Development, and Manufacturing Organization (CRDMO) WuXi Biologics (HKG: 2269) has announced multiple...
Biden’s Executive Order Boosts US Bio-Economy, Targets China’s Biotech Rise
US President Joe Biden signed an executive order on Monday, outlining steps to bolster the...
WuXi Biologics Partners with AstraZeneca for Local Production of Evusheld
China-based WuXi Biologics (HKG: 2269), a leading Contract Research, Development, and Manufacturing Organization (CRDMO), announced...
CANbridge Pharmaceuticals Doses First Patient in CAN103 Gaucher Disease Trial
China-based rare disease firm CANbridge Pharmaceuticals announced the dosing of the first patient in a...